Pasricha Trisha S, Pasricha Pankaj J
Osler Medical Training Program, Department of Medicine, Johns Hopkins Hospital, 1800 Orleans Street, Baltimore, MD 21287, USA.
Department of Gastroenterology, Johns Hopkins Hospital, Ross 958, 720 Rutland Avenue, Baltimore, MD 21205, USA.
Gastrointest Endosc Clin N Am. 2019 Jan;29(1):97-106. doi: 10.1016/j.giec.2018.08.007. Epub 2018 Sep 28.
Refractory gastroparesis is among the most difficult therapeutic challenges in gastroenterology. Pyloric dysfunction has been described in a subset of patients with gastroparesis, prompting experimentation with botulinum toxin injections into the pylorus, which is relatively safe and has been successfully used in other gastrointestinal disorders. However, causality between pyloric dysfunction and symptoms of gastroparesis has never been demonstrated. Although several open-label studies showed initial promise, 2 randomized clinical trials failed to elicit a difference in clinical outcomes in botulinum toxin versus placebo. Based on current evidence, further use of botulinum toxin for gastroparesis is discouraged outside of a research trial.
难治性胃轻瘫是胃肠病学中最具挑战性的治疗难题之一。在一部分胃轻瘫患者中已发现幽门功能障碍,这促使人们尝试向幽门注射肉毒杆菌毒素,该方法相对安全且已成功应用于其他胃肠道疾病。然而,幽门功能障碍与胃轻瘫症状之间的因果关系从未得到证实。尽管几项开放标签研究初步显示出前景,但两项随机临床试验未能发现肉毒杆菌毒素与安慰剂在临床结局上存在差异。基于目前的证据,不建议在研究试验之外进一步将肉毒杆菌毒素用于治疗胃轻瘫。